SG11202106166TA - Peptide binder - Google Patents
Peptide binderInfo
- Publication number
- SG11202106166TA SG11202106166TA SG11202106166TA SG11202106166TA SG11202106166TA SG 11202106166T A SG11202106166T A SG 11202106166TA SG 11202106166T A SG11202106166T A SG 11202106166TA SG 11202106166T A SG11202106166T A SG 11202106166TA SG 11202106166T A SG11202106166T A SG 11202106166TA
- Authority
- SG
- Singapore
- Prior art keywords
- peptide binder
- peptide
- binder
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/62—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP18306657 | 2018-12-11 | ||
EP18306659 | 2018-12-11 | ||
EP18306658 | 2018-12-11 | ||
PCT/EP2019/084433 WO2020120479A1 (en) | 2018-12-11 | 2019-12-10 | Peptide binder |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202106166TA true SG11202106166TA (en) | 2021-07-29 |
Family
ID=68806785
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202106167XA SG11202106167XA (en) | 2018-12-11 | 2019-12-10 | Insulin conjugates |
SG11202106168VA SG11202106168VA (en) | 2018-12-11 | 2019-12-10 | Insulin analogs having reduced insulin receptor binding affinity |
SG11202106166TA SG11202106166TA (en) | 2018-12-11 | 2019-12-10 | Peptide binder |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202106167XA SG11202106167XA (en) | 2018-12-11 | 2019-12-10 | Insulin conjugates |
SG11202106168VA SG11202106168VA (en) | 2018-12-11 | 2019-12-10 | Insulin analogs having reduced insulin receptor binding affinity |
Country Status (15)
Country | Link |
---|---|
US (2) | US11098102B2 (zh) |
EP (3) | EP3893934A1 (zh) |
JP (3) | JP2022513776A (zh) |
KR (3) | KR20210102346A (zh) |
CN (3) | CN113423691A (zh) |
AU (3) | AU2019398402A1 (zh) |
BR (3) | BR112021011099A2 (zh) |
CA (3) | CA3122636A1 (zh) |
CO (1) | CO2021007453A2 (zh) |
IL (3) | IL283803A (zh) |
MX (3) | MX2021006970A (zh) |
PH (1) | PH12021551339A1 (zh) |
SG (3) | SG11202106167XA (zh) |
TW (3) | TW202039438A (zh) |
WO (3) | WO2020120479A1 (zh) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112876388B (zh) * | 2021-01-14 | 2023-03-31 | 山东大学 | 一种gpr120激动剂及其制备方法与应用 |
CN116162147B (zh) * | 2021-11-24 | 2023-10-03 | 成都奥达生物科技有限公司 | 一种长效胰岛素类似物 |
CN114230451A (zh) * | 2021-12-29 | 2022-03-25 | 上海药坦药物研究开发有限公司 | 卤代酸类化合物的制备方法 |
WO2023144277A1 (en) * | 2022-01-26 | 2023-08-03 | Sanofi | Insulin conjugates |
WO2023247640A1 (en) | 2022-06-23 | 2023-12-28 | Sanofi | Single chain insulins and fc conjugates thereof |
CN115850385B (zh) * | 2022-07-04 | 2023-08-11 | 北京惠之衡生物科技有限公司 | 一种促表达肽及其应用 |
WO2024051787A1 (zh) * | 2022-09-09 | 2024-03-14 | 北京惠之衡生物科技有限公司 | 一种长效酰化胰岛素衍生物及其应用 |
Family Cites Families (66)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU682061B2 (en) | 1993-09-17 | 1997-09-18 | Novo Nordisk A/S | Acylated insulin |
PL183698B1 (pl) | 1995-03-17 | 2002-06-28 | Novo Nordisk As | Pochodna insuliny, kompozycja farmaceutyczna i zastosowanie pochodnej insuliny |
US6451970B1 (en) | 1996-02-21 | 2002-09-17 | Novo Nordisk A/S | Peptide derivatives |
CA2306877A1 (en) | 1997-10-24 | 1999-05-06 | Eli Lilly And Company | Insoluble insulin compositions |
KR20070029247A (ko) | 2004-07-08 | 2007-03-13 | 노보 노르디스크 에이/에스 | 폴리펩티드 연장 태그 |
EP1846447B1 (en) | 2005-02-02 | 2013-08-21 | Novo Nordisk A/S | Insulin derivatives |
JP4933455B2 (ja) | 2005-02-02 | 2012-05-16 | ノヴォ ノルディスク アー/エス | 新規のインスリン誘導体 |
WO2007020256A1 (en) | 2005-08-16 | 2007-02-22 | Novo Nordisk A/S | Method for making mature insulin polypeptides |
JP5202338B2 (ja) | 2006-02-27 | 2013-06-05 | ノボ・ノルデイスク・エー/エス | 新規インシュリン誘導体 |
WO2007104736A2 (en) | 2006-03-13 | 2007-09-20 | Novo Nordisk A/S | Acylated single chain insulin |
WO2007128815A1 (en) | 2006-05-09 | 2007-11-15 | Novo Nordisk A/S | Insulin derivative |
AU2007247109B2 (en) | 2006-05-09 | 2012-03-15 | Novo Nordisk A/S | Insulin derivative |
CN101573133B (zh) | 2006-07-31 | 2014-08-27 | 诺沃-诺迪斯克有限公司 | Peg化延长的胰岛素 |
ES2601839T3 (es) | 2006-09-22 | 2017-02-16 | Novo Nordisk A/S | Análogos de insulina resistentes a proteasas |
WO2008049711A1 (en) | 2006-10-27 | 2008-05-02 | Novo Nordisk A/S | Peptide extended insulins |
GB0621973D0 (en) * | 2006-11-03 | 2006-12-13 | Philogen Spa | Binding molecules and uses thereof |
JP5688969B2 (ja) | 2007-07-16 | 2015-03-25 | ノボ・ノルデイスク・エー/エス | プロテアーゼに対して安定しているペグ化インスリンアナログ |
CA2695970A1 (en) | 2007-08-15 | 2009-02-19 | Novo Nordisk A\S | Insulin analogues with an acyl and aklylene glycol moiety |
US8962794B2 (en) | 2007-08-15 | 2015-02-24 | Novo Nordisk A/S | Insulins with an acyl moiety comprising repeating units of alkylene glycol containing amino acids |
JP5547083B2 (ja) | 2007-11-20 | 2014-07-09 | アンブルックス,インコーポレイテッド | 修飾されたインスリンポリペプチドおよびそれらの使用 |
WO2009112583A2 (en) * | 2008-03-14 | 2009-09-17 | Novo Nordisk A/S | Protease-stabilized insulin analogues |
MX2010009850A (es) | 2008-03-18 | 2010-09-30 | Novo Nordisk As | Analogos de insulina acilados y etabilizados contra proteasas. |
CN102065903B (zh) | 2008-04-01 | 2015-02-18 | 诺沃-诺迪斯克有限公司 | 胰岛素清蛋白缀合物 |
PL219335B1 (pl) | 2008-07-04 | 2015-04-30 | Inst Biotechnologii I Antybiotyków | Pochodna insuliny lub jej farmaceutycznie dopuszczalna sól, jej zastosowanie oraz zawierająca ją kompozycja farmaceutyczna |
CN102202683A (zh) | 2008-10-30 | 2011-09-28 | 诺沃-诺迪斯克有限公司 | 用少于每日一次的注射频率注射胰岛素来治疗糖尿病 |
EP2376531A1 (en) | 2008-12-09 | 2011-10-19 | Novo Nordisk A/S | Novel insulin analogues |
CA2747490C (en) | 2008-12-19 | 2017-02-14 | Indiana University Research And Technology Corporation | Insulin analogs |
CA2744558A1 (en) | 2008-12-19 | 2010-07-15 | Indiana University Research And Technology Corporation | Amide-based insulin prodrugs |
WO2010130638A1 (en) * | 2009-05-14 | 2010-11-18 | Evotec Ag | Sulfonamide compounds, pharmaceutical compositions and uses thereof |
JP5969461B2 (ja) * | 2010-04-27 | 2016-08-17 | ジーランド ファーマ アクティーゼルスカブ | Glp−1受容体作動薬とガストリンとのペプチド複合体及びその使用 |
CN107029212A (zh) | 2010-05-10 | 2017-08-11 | 诺沃—诺迪斯克有限公司 | 用于制备胰岛素‑锌复合物的方法 |
JP5912112B2 (ja) | 2010-06-24 | 2016-04-27 | インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションIndiana University Research And Technology Corporation | アミド系インスリンプロドラッグ |
JP2013540771A (ja) | 2010-10-15 | 2013-11-07 | ノヴォ ノルディスク アー/エス | 新規n末端修飾インスリン誘導体 |
JP6058646B2 (ja) | 2011-06-15 | 2017-01-11 | ノヴォ ノルディスク アー/エス | 多置換インスリン |
CN104011070A (zh) | 2011-12-15 | 2014-08-27 | 爱德迪安(北京)生物技术有限公司 | 具有降血糖作用的化合物、组合物及其用途 |
CA2858253A1 (en) | 2011-12-15 | 2013-06-20 | Shanghai Hengrui Pharmaceutical Co., Ltd. | Human insulin analogue and acylated derivative thereof |
US20140357838A1 (en) | 2011-12-21 | 2014-12-04 | Novo Nordisk A/S | N-Terminally Modified Insulin Derivatives |
EP2869830B1 (en) | 2012-07-09 | 2016-10-12 | Novo Nordisk A/S | Novel use of insulin derivatives |
EP2914620B1 (en) | 2012-11-05 | 2018-08-08 | Case Western Reserve University | Long-acting single-chain insulin analogues |
CN114989289A (zh) | 2013-02-26 | 2022-09-02 | 韩美药品株式会社 | 新颖的胰岛素类似物及其用途 |
KR20150131213A (ko) | 2013-03-14 | 2015-11-24 | 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 | 인슐린-인크레틴 접합체들 |
WO2014147141A1 (en) | 2013-03-20 | 2014-09-25 | Novo Nordisk A/S | Insulin dosing regimen |
EP2991672A1 (en) | 2013-04-30 | 2016-03-09 | Novo Nordisk A/S | Novel administration regime |
EP3004156A1 (en) | 2013-06-07 | 2016-04-13 | Novo Nordisk A/S | Method for making mature insulin polypeptides |
WO2015016293A1 (ja) * | 2013-08-02 | 2015-02-05 | 国立大学法人 富山大学 | (ベンゼンスルホニルアミノ)ベンズアミド誘導体およびそれらを有効成分とするship2阻害剤 |
MA39301A1 (fr) | 2014-01-20 | 2018-01-31 | Hanmi Pharmaceutical Co Ltd | Insuline à action prolongée et utilisation associée |
AR099569A1 (es) | 2014-02-28 | 2016-08-03 | Novo Nordisk As | Derivados de insulina y los usos médicos de estos |
AR100639A1 (es) * | 2014-05-29 | 2016-10-19 | Hanmi Pharm Ind Co Ltd | Composición para tratar diabetes que comprende conjugados de análogos de insulina de acción prolongada y conjugados de péptidos insulinotrópicos de acción prolongada |
KR20160001391A (ko) | 2014-06-27 | 2016-01-06 | 한미약품 주식회사 | 신규한 지속형 인슐린 아날로그 결합체 및 이의 용도 |
WO2016001185A1 (en) | 2014-07-02 | 2016-01-07 | Novo Nordisk A/S | Dosage regimen for the treatment of diabetes |
KR20160007295A (ko) | 2014-07-11 | 2016-01-20 | 한미약품 주식회사 | 인슐린 아날로그 |
US20180000742A1 (en) | 2015-01-29 | 2018-01-04 | Novo Nordisk A/S | Pharmaceutical Composition for Oral Insulin Administration Comprising a Tablet Core and a Polyvinyl Alcohol Coating |
WO2016172269A2 (en) | 2015-04-20 | 2016-10-27 | University Of Utah Research Foundation | Insulin analogs having shortened b chain peptides and associated methods |
JP2018531901A (ja) | 2015-08-25 | 2018-11-01 | ノヴォ ノルディスク アー/エス | 新規インスリン誘導体及びその医学的使用 |
CN108368163A (zh) | 2015-08-25 | 2018-08-03 | 诺和诺德股份有限公司 | 新型胰岛素衍生物及其医学用途 |
DK3341044T3 (da) | 2015-08-25 | 2020-02-17 | Novo Nordisk As | Medicinsk injektionsindretning med et rensningskammer |
PL239062B1 (pl) | 2016-01-22 | 2021-11-02 | Inst Biotechnologii I Antybiotykow | Sposób wytwarzania insuliny i jej pochodnych |
EP3495384A4 (en) | 2016-08-02 | 2020-02-26 | Jiangsu Hengrui Medicine Co., Ltd. | ACYLATED DERIVATIVE OF HUMAN INSULIN OR ANALOGUE OF IT |
JP7158378B2 (ja) * | 2016-09-23 | 2022-10-21 | ハンミ ファーマシューティカル カンパニー リミテッド | インスリン受容体との結合力が減少された、インスリンアナログ及びその用途 |
JP7286160B2 (ja) | 2016-11-21 | 2023-06-05 | ケース ウェスタン リザーブ ユニバーシティ | 安定性が増強された速効性インスリン類似体 |
AU2017378102B2 (en) | 2016-12-16 | 2022-10-13 | Novo Nordisk A/S | Insulin containing pharmaceutical compositions |
AU2018215840A1 (en) | 2017-02-03 | 2019-08-01 | Hanmi Pharm. Co., Ltd. | Long-Acting Conjugate Of A Physiologically Active Material And Use Thereof |
US11752216B2 (en) | 2017-03-23 | 2023-09-12 | Hanmi Pharm. Co., Ltd. | Insulin analog complex with reduced affinity for insulin receptor and use thereof |
JOP20190273A1 (ar) | 2017-05-26 | 2019-11-24 | Lilly Co Eli | مركب إنسولين معالج بأسيل |
KR20190036956A (ko) | 2017-09-28 | 2019-04-05 | 한미약품 주식회사 | 지속형 단쇄 인슐린 아날로그 및 이의 결합체 |
WO2019125879A2 (en) | 2017-12-18 | 2019-06-27 | Merck Sharp & Dohme Corp. | Conjugate based systems for controlled insulin delivery |
-
2019
- 2019-12-10 WO PCT/EP2019/084433 patent/WO2020120479A1/en active Application Filing
- 2019-12-10 BR BR112021011099-2A patent/BR112021011099A2/pt unknown
- 2019-12-10 AU AU2019398402A patent/AU2019398402A1/en active Pending
- 2019-12-10 CN CN201980091302.5A patent/CN113423691A/zh active Pending
- 2019-12-10 BR BR112021011050-0A patent/BR112021011050A2/pt unknown
- 2019-12-10 US US16/709,208 patent/US11098102B2/en active Active
- 2019-12-10 AU AU2019398579A patent/AU2019398579A1/en active Pending
- 2019-12-10 BR BR112021011156-5A patent/BR112021011156A2/pt unknown
- 2019-12-10 JP JP2021533149A patent/JP2022513776A/ja active Pending
- 2019-12-10 CA CA3122636A patent/CA3122636A1/en active Pending
- 2019-12-10 TW TW108145067A patent/TW202039438A/zh unknown
- 2019-12-10 SG SG11202106167XA patent/SG11202106167XA/en unknown
- 2019-12-10 AU AU2019398658A patent/AU2019398658A1/en active Pending
- 2019-12-10 KR KR1020217021395A patent/KR20210102346A/ko unknown
- 2019-12-10 MX MX2021006970A patent/MX2021006970A/es unknown
- 2019-12-10 TW TW108145065A patent/TW202039437A/zh unknown
- 2019-12-10 WO PCT/EP2019/084400 patent/WO2020120463A1/en unknown
- 2019-12-10 SG SG11202106168VA patent/SG11202106168VA/en unknown
- 2019-12-10 KR KR1020217021394A patent/KR20210102345A/ko not_active Application Discontinuation
- 2019-12-10 JP JP2021533153A patent/JP2022511567A/ja active Pending
- 2019-12-10 CN CN201980091301.0A patent/CN113395982A/zh active Pending
- 2019-12-10 CN CN201980091275.1A patent/CN113396157A/zh active Pending
- 2019-12-10 EP EP19816338.8A patent/EP3893934A1/en active Pending
- 2019-12-10 MX MX2021006969A patent/MX2021006969A/es unknown
- 2019-12-10 WO PCT/EP2019/084427 patent/WO2020120477A1/en unknown
- 2019-12-10 KR KR1020217021396A patent/KR20210102347A/ko unknown
- 2019-12-10 JP JP2021533148A patent/JP2022513775A/ja active Pending
- 2019-12-10 MX MX2021006972A patent/MX2021006972A/es unknown
- 2019-12-10 TW TW108145066A patent/TW202039539A/zh unknown
- 2019-12-10 EP EP19816708.2A patent/EP3894391A1/en active Pending
- 2019-12-10 CA CA3122632A patent/CA3122632A1/en active Pending
- 2019-12-10 EP EP19816341.2A patent/EP3894435A1/en active Pending
- 2019-12-10 CA CA3122637A patent/CA3122637A1/en active Pending
- 2019-12-10 SG SG11202106166TA patent/SG11202106166TA/en unknown
-
2021
- 2021-05-25 US US17/329,558 patent/US20220048968A1/en active Pending
- 2021-06-07 PH PH12021551339A patent/PH12021551339A1/en unknown
- 2021-06-08 IL IL283803A patent/IL283803A/en unknown
- 2021-06-08 CO CONC2021/0007453A patent/CO2021007453A2/es unknown
- 2021-06-08 IL IL283800A patent/IL283800A/en unknown
- 2021-06-08 IL IL283801A patent/IL283801A/en unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZAA201801346S (en) | Case | |
ZAA201801143S (en) | Case | |
IL283803A (en) | binds peptides | |
IL281762A (en) | Arginase proteins1 | |
GB201808868D0 (en) | Binder | |
IL284006A (en) | Mitochondria-targeted peptides | |
IL269477A (en) | Polypeptides that bind to IL-1R-1 | |
EP3750824C0 (en) | BINDING DEVICE | |
GB2579182B (en) | Binder materials | |
GB201810052D0 (en) | Polypeptide | |
GB201814440D0 (en) | Peptide | |
GB201803074D0 (en) | Peptide | |
GB201807863D0 (en) | Peptides | |
GB201806181D0 (en) | Peptides | |
GB201806655D0 (en) | Polypeptide | |
GB201805809D0 (en) | Peptides | |
GB201805807D0 (en) | Peptides | |
GB201805801D0 (en) | Peptides | |
GB201918693D0 (en) | Peptide | |
GB201912632D0 (en) | Peptide | |
GB201801959D0 (en) | Binding polypeptides | |
GB201811755D0 (en) | Polypeptides | |
GB201807890D0 (en) | Polypeptides | |
GB201807893D0 (en) | Polypeptides | |
GB201807895D0 (en) | Polypeptides |